Matthew Plunkett, EVP, Corporate Development at CTI BIOPHARMA CORP (CTIC), sold 12,000 shares at $2.37 ($28K) on 2015-01-05, disclosed to the SEC on 2015-01-07.
Scheduled sale ($28k) by EVP, Corporate Development under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $2.34 | 1,000 | $2K | 8.2% |
| 2 | $2.35 | 300 | $705 | 2.5% |
| 3 | $2.35 | 100 | $235 | 0.8% |
| 4 | $2.36 | 1,000 | $2K | 8.3% |
| 5 | $2.36 | 2,300 | $5K | 19.1% |
| 6 | $2.37 | 5,700 |
| $14K |
| 47.6% |
| 7 | $2.37 | 600 | $1K | 5.0% |
| 8 | $2.38 | 1,000 | $2K | 8.4% |
| Total | $2.36 avg | 12,000 | $28K | 100% |
| Filing → |
| CTIC | SELL | 2016-01-06 | $15K | — | Filing → |
| CTIC | SELL | 2015-12-04 | $9K | — | Filing → |
| CTIC | SELL | 2015-11-06 | $14K | — | Filing → |